AURORA, ON, June 26 /CNW/ - Helix BioPharma Corp. (TSX: HBP - News), a developer of novel cancer therapeutics, today announced that Dr. Heman Chao, VP Research, will be presenting a poster at the 5th Annual Congress on Recombinant Antibodies Conference, in Zurich Switzerland. The poster entitled “L-DOS47 - a novel lung adenocarcinoma specific immuno-conjugate therapeutic”, highlights the ability of L-DOS47 to target and kill lung tumour cells in vitro and in tumour bearing mice, as well as L-DOS47’s ability to enhance the effect of weakly basic chemotherapeutics. L-DOS47 is the first immuno-conjugate therapeutic candidate derived from Helix’s novel anti-cancer DOS47 platform technology.
